Anocca

Anocca is a clinical-stage biopharmaceutical company based in Södertälje, Sweden, focused on developing precision T-cell receptor-engineered T cell (TCR-T) therapies for challengin

g diseases, particularly untreatable solid tumors. Founded in 2014, Anocca aims to decode T-cell immunity and create innovative T-cell immunotherapies. The company employs around 120-130 professionals, including scientists and engineers, in state-of-the-art facilities. Anocca's primary offerings include a library of TCR-T cell therapies, with over 40 assets targeting various cancer types. Its most advanced therapy is aimed at the KRAS G12V mutation in pancreatic cancer, currently entering a Phase 1/2a clinical trial. In addition to oncology, Anocca is exploring applications for infectious and autoimmune diseases, as well as developing vaccination strategies that utilize T-cell immunity. The company serves healthcare providers and patients, particularly those facing the most difficult-to-treat cancers, and is expanding its reach with an international focus on clinical trials in Europe.